Evidence map›Paper›PMID 24764295›Full record

ArticleThe Journal of biological chemistry2014

Non-repair pathways for minimizing protein isoaspartyl damage in the yeast Saccharomyces cerevisiae.

Alexander N Patananan, Joseph Capri, Julian P Whitelegge, Steven G Clarke

Abstract read
In one paragraph

Article in The Journal of biological chemistry, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed.

  1. Article
  2. Article
  3. Human Protein-l-isoaspartateBiochemistry · 2022
    Article
  4. Article
  5. Article
  6. Functional divergence of annotated l-isoaspartateThe Journal of biological chemistry · 2019
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Enzymatic attributes of an l-isoaspartyl methyltransferase fromBiochemistry and biophysics reports · 2015
    Article
  16. Article
  17. Article
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Alexander N PatanananFrom the Department of Chemistry and Biochemistry and the Molecular Biology Institute and.
Joseph Caprithe Pasarow Mass Spectrometry Laboratory, Neuropsychiatric Institute-Semel Institute for Neuroscience and Human Behavior, UCLA, Los Angeles, California 90095.
Julian P Whiteleggethe Pasarow Mass Spectrometry Laboratory, Neuropsychiatric Institute-Semel Institute for Neuroscience and Human Behavior, UCLA, Los Angeles, California 90095.
Steven G ClarkeFrom the Department of Chemistry and Biochemistry and the Molecular Biology Institute and clarke@chem.ucla.edu.

Funding

Transgenic & Knock-out MouseP30DK063491 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI MILES Frome WILKINSON · 2003 to 2026
$40.4M
UCLA NIGMS T32 Program AssessmentT32GM007185 · NIGMS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI TORRES, JORGE · 1985 to 2020
$21.7M
CONTROL OF EUCARYOTIC FUNCTION BY METHYLATIONR37GM026020 · NIGMS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI CLARKE, STEVEN G · 2000 to 2009
$5.0M
CONTROL OF EUKARYOTIC MEMBRANE FUNCTION BY METHYLATIONR01GM026020 · NIGMS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI CLARKE, STEVEN G · 1985 to 2013
$2.1M
Linked Protein Repair, Proteolysis, and Oxidation in AgingR21AG032303 · NIA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI CLARKE, STEVEN G · 2008 to 2009
$394k
NIA NIH HHS AG032303NIA NIH HHS R21 AG032303NIDDK NIH HHS P30 DK063491NIGMS NIH HHS GM007185NIGMS NIH HHS GM026020NIGMS NIH HHS R01 GM026020NIGMS NIH HHS R37 GM026020NIGMS NIH HHS T32 GM007185
6 · The paper itself

Abstract

The spontaneous degradation of asparaginyl and aspartyl residues to isoaspartyl residues is a common type of protein damage in aging organisms. Although the protein-l-isoaspartyl (d-aspartyl) O-methyltransferase (EC 2.1.1.77) can initiate the repair of l-isoaspartyl residues to l-aspartyl residues in most organisms, no gene homolog or enzymatic activity is present in the budding yeast Saccharomyces cerevisiae. Therefore, we used biochemical approaches to elucidate how proteins containing isoaspartyl residues are metabolized in this organism. Surprisingly, the level of isoaspartyl residues in yeast proteins (50-300 pmol of isoaspartyl residues/mg of protein extract) is comparable with organisms with protein-l-isoaspartyl (d-aspartyl) O-methyltransferase, suggesting a novel regulatory pathway. Interfering with common protein quality control mechanisms by mutating and inhibiting the proteasomal and autophagic pathways in vivo did not increase isoaspartyl residue levels compared with wild type or uninhibited cells. However, the inhibition of metalloproteases in in vitro aging experiments by EDTA resulted in an ∼3-fold increase in the level of isoaspartyl-containing peptides. Characterization by mass spectrometry of these peptides identified several proteins involved in metabolism as targets of isoaspartyl damage. Further analysis of these peptides revealed that many have an N-terminal isoaspartyl site and originate from proteins with short half-lives. These results suggest that one or more metalloproteases participate in limiting isoaspartyl formation by robust proteolysis.

Indexed as

AnimalsHumansIsoaspartic AcidMetalloproteasesPeptidesPhylogenyProtein D-Aspartate-L-Isoaspartate MethyltransferaseProteolysisSaccharomyces cerevisiaeSaccharomyces cerevisiae ProteinsIsoaspartic AcidMetalloproteasesPeptidesProtein D-Aspartate-L-Isoaspartate MethyltransferaseSaccharomyces cerevisiae ProteinsAgingIsoaspartyl ResiduesProtein DeamidationProtein l-Isoaspartyl MethyltransferaseProtein MethylationProtein StabilityProtein TurnoverProteolytic EnzymeYeast Physiology

Identifiers

PMID24764295
PMCPMC4059137

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.